Zobrazeno 1 - 10
of 470
pro vyhledávání: '"Larry E. Kun"'
Autor:
Ibrahim eQaddoumi, Mehmet eKocak, Atmaram S. Pai-Panandiker, Gregory T. Armstrong, Cynthia eWetmore, John R. Crawford, Tong eLin, James M Boyett, Larry E. Kun, Fredrick A. Boop, Thomas E. Merchant, David W Ellison, Amar eGajjar, Alberto eBroniscer
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Background. Epidermal growth factor receptor is overexpressed in most pediatric high-grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted a phase II trial of erlotinib and local radiotherapy in children with newly
Externí odkaz:
https://doaj.org/article/102abc8e336441c8bd6189bc470514b0
Autor:
Tom Curran, Richard J. Gilbertson, James M. Boyett, Naoko Takebe, Dana Wallace, Murali Chintagumpala, Stewart Goldman, Roger J. Packer, Larry E. Kun, Sue Kaste, David W. Ellison, Clinton F. Stewart, Amar Gajjar
Purpose: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma.Experimental design: Initially, vismodegib was administered daily at 85
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044aeb59b1dd16c65d049e326fb982ea
https://doi.org/10.1158/1078-0432.c.6522327
https://doi.org/10.1158/1078-0432.c.6522327
Autor:
Tom Curran, Richard J. Gilbertson, James M. Boyett, Naoko Takebe, Dana Wallace, Murali Chintagumpala, Stewart Goldman, Roger J. Packer, Larry E. Kun, Sue Kaste, David W. Ellison, Clinton F. Stewart, Amar Gajjar
PDF file - 156K, Supplementary Fig. S1. Concentration-time plots of the first 72 hours after administration of the first vismodegib dose during Course 1 to the patients in the initial cohort: 6 received 85 mg/m2 (Figure A & B), and 7 received 170 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26899133026bacfbf4bfddf5759a4122
https://doi.org/10.1158/1078-0432.22451901
https://doi.org/10.1158/1078-0432.22451901
Autor:
Tom Curran, Richard J. Gilbertson, James M. Boyett, Naoko Takebe, Dana Wallace, Murali Chintagumpala, Stewart Goldman, Roger J. Packer, Larry E. Kun, Sue Kaste, David W. Ellison, Clinton F. Stewart, Amar Gajjar
PDF file - 104K, Supplementary Table S1. Vismodegib Dosing Strategy Supplementary Table S2. Commonly Reported Adverse Events According to Grade Supplementary Table S3. Pharmacokinetics of Unbound Vismodegib in Pediatric Patients with Medulloblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1065899e0687d584c3cca4ce9b81772f
https://doi.org/10.1158/1078-0432.22451898.v1
https://doi.org/10.1158/1078-0432.22451898.v1
Autor:
Stephanie A. Terezakis, Kenneth Wong, Kenneth J. Cohen, Mike Makrigiorgos, Vinai Gondi, David R. Grosshans, Jeff M. Michalski, Arthur K. Liu, Dragan Mirkovic, Tina Young Poussaint, Torunn I. Yock, Kry Stephen, Hanne M. Kooy, John A. Kalapurakal, Stella Flampouri, Kavita Mishra, Stephanie M. Perkins, Daphne A. Haas-Kogan, Harald Paganetti, Daniel J. Indelicato, Maryam Fouladi, Radhe Mohan, Thomas J. Fitzgerald, Shannon M. MacDonald, Anita Mahajan, Natia Esiashvili, Bhadrasain Vikram, Larry E. Kun, Jeff Buchsbaum
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 101:152-168
Purpose Proton therapy can allow for superior avoidance of normal tissues. A widespread consensus has been reached that proton therapy should be used for patients with curable pediatric brain tumor to avoid critical central nervous system structures.
Autor:
Melissa M. Hudson, Sue C. Kaste, Tara M. Brinkman, Gregory T. Armstrong, Kirsten K. Ness, Nickhill Bhakta, Deborah B. Crom, Daniel A. Mulrooney, John T. Sandlund, Kevin R. Krull, Wassim Chemaitilly, Nan Zhang, Larry E. Kun, Wei Liu, Kumar Srivastava, Leslie L. Robison, Matthew J. Ehrhardt, Daniel M. Green
Publikováno v:
Yearbook of Paediatric Endocrinology.
Background Survivors of childhood non-Hodgkin lymphoma (NHL) are at increased risk for chronic health conditions. The objective of this study was to characterize health conditions, neurocognitive function, and physical performance among a clinically
Autor:
Mehmet Kocak, Lindsay Kilburn, Eugene Hwang, Alberto Broniscer, Annabelle Lemenuel-Diot, Arnold C. Paulino, Justin N. Baker, Murali Chintagumpala, Tina Young Poussaint, James M. Boyett, Patricia Baxter, Christine Lopez-Diaz, Christine McIntyre, Jack Su, Larry E. Kun, Maryam Fouladi, Susan M. Blaney
Background We conducted a phase II study of oral capecitabine rapidly disintegrating tablets given concurrently with radiation therapy (RT) to assess progression-free survival (PFS) in children with newly diagnosed diffuse intrinsic pontine gliomas (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d15be7208cdeacd19e11b247aaae2a6
https://europepmc.org/articles/PMC5774861/
https://europepmc.org/articles/PMC5774861/
Autor:
Mehmet Kocak, Maryam Fouladi, Larry E. Kun, Richard J. Gilbertson, Susan M. Blaney, Anuradha Banerjee, Lindsay Kilburn, Stewart Goldman, James M. Boyett, Cynthia Wetmore, Jack Su, Murali Chintagumpala, Rodney Decker
Publikováno v:
Neuro-Oncology. 17:303-311
We sought to estimate the maximum tolerated or recommended phase 2 dose and describe the pharmacokinetics and toxicities of enzastaurin, an oral inhibitor of protein kinase Cβ, in children with recurrent central nervous system malignancies.Enzastaur
Autor:
Caleb Smith, Michael Fisher, Anu Banerjee, Maryam Fouladi, Stewart Goldman, Ian F. Pollack, Shengjie Wu, Roger J. Packer, David C. Turner, Rishi Lulla, Brian R. Rood, Clinton F. Stewart, Arzu Onar-Thomas, Larry E. Kun, Tina Young-Pouissant, James M. Boyett
Publikováno v:
Journal of Neuro-Oncology. 121:217-224
PTC299 is a novel, orally-bioavailable small molecule that selectively inhibits vascular endothelial growth factor receptor protein synthesis at the post-transcriptional level. Based on promising preclinical results, we conducted a pediatric phase I
Autor:
David W. Ellison, Jordan M. Ross, Thomas E. Merchant, Cynthia Wetmore, Gregory T. Armstrong, Deokumar Srivastava, Paul Klimo, Larry E. Kun, Karen Tsui, Amar Gajjar, Brent A. Orr, Chenghong Li, Alberto Broniscer, Leslie L. Robison, Frederick A. Boop
Publikováno v:
Neuro-Oncology. 17:448-456
Background Multimodal therapy has improved survival for some childhood CNS tumors. However, whether risk for subsequent neoplasms (SNs) also increases is unknown. We report the cumulative incidence of, and risk factors for, SNs after a childhood prim